Phosphate binders in CKD - Past, present, and future

Journal, Indian Academy of Clinical Medicine

Volumn 10, Issue 1-2, 2009, Pages 43-45

  Agarwal, Nagina ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; COLESTILAN; LANTHANUM; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; NICOTINAMIDE; PHOSPHATE BINDING AGENT; SEVELAMER;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BLURRED VISION; BONE DISEASE; BRAIN DISEASE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HEARTBURN; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MORTALITY; MYOPATHY; NONHUMAN; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; REVIEW; VOMITING;

EID: 67749130821     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Joseph A. Coladonato. Control of hyperphosphataemia among patients with end-stage renal disease. J Am Soc Nephrol 2005;16 (supp 12): S107-14.
2. Levin EG, Levin NW. National Kidney Foundation. K/DOQ1 clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl. 3): S1-201.
3. Gotch FA, Panlilio F, Sergeyeva O et al. A kinetic model of inorganic phosphorous mass balance in haemodialysis therapy. Blood Purif 2003; 21: 51-57 (Pubitemid 36173349)
4. Minutolo R, Bellizi V, Cioff M et al. Post-dialytic rebound of serum phosphorous: pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13: 1046-1054 (Pubitemid 34274102)
5. Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purify 2005; 23 (Suppl 1): 2-11. (Pubitemid 44681102)
6. Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17 (Suppl 2): 9-12. (Pubitemid 34413718)
7. Coburn JW, Mischel MG, Goodman WG et al. Calcium citrate markedly enhances aluminium absorption from aluminium hydroxide. AM J Kidney Dis 1991; 17: 708-711
8. Mai M, Emmett M, Sheikh MS et al. Calcium acetate, an effective phosphorous binder in patients with renal failure. Kidney Int 1989; 36: 690-695 (Pubitemid 19239562)
9. Salusky IB, Goodman WG. Adynamic renal dystrophy: Is there a problem? J Am Soc Nephrol 2001; 12: 1978-1985
10. Kurz P, Monier-Faugere HC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861 (Pubitemid 24272045)
11. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med 2000; 342: 1478-1483 (Pubitemid 30318271)
12. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcification in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021 (Pubitemid 30410374)
13. Guillot AP, Hood VL, Runge CF et al. The use of magnesium containing phosphate binders in patients with end-stage renal disease on maintenance haemodialysis. Nephron 1982; 30: 114-117
14. Delmez JA, Kelber J, Norwood KY et al. Magnesium carbonate as a phosphorous binder: a prospective, controlled, cross over study. Kidney Int 1996; 49: 163-167 (Pubitemid 26024233)
15. Castro R, Herman A, Ferriera C et al. Renagel efficacy in severe secondary hyperparathyroidism. Nephrologia 2002; 22: 448-455
16. Wilkes BM, Reiner D, Kern M et al. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (Renagel) in dialysis patients. Clin Nephrol 1998; 50: 381-386 (Pubitemid 28552240)
17. Ferramosca E, Burke S, Chsen-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance haemodialysis patients. Am Heart J 2005; 149: 820-825 (Pubitemid 40718876)
18. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidaemia and chronic inflammation in maintenance haemodialysis patients. Ren Fail 2005; 27: 361-365 (Pubitemid 40993682)
19. Garg JP, Chasen Taber S, Blair A et al. Effect of sevelamer and calcium-based phosphate binders on uric acid concentration in patients undergoing haemodialysis: a randomised clinical trial. Arthritis Rheum 2005; 52: 290-295 (Pubitemid 40129261)
20. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney Int 2002; 62: 245-252 (Pubitemid 34754068)
21. Sparagus SM. A comparative review of efficacy and safety of established phosphate binder: calcium, sevelamer and lanthanum carbonate. Cure Med Res Opin 2007; 23 (12): 3167-3175
22. Borras M, Macco MP, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients. Perit Dial Int 2002; 16: 429-436 (Pubitemid 36131512)
23. Huthison AJ, Maes B, Vanwallegham J et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract 2006; 102: 61-71. (Pubitemid 43087563)
24. Drijeke TB. Lanthanum carbonate as a first-line phosphate binder: the "cons". Semin Dial 2007; 20 (4): 329-332
25. de Freitas D, Donne RL, Hutchison AJ. Lanthanum carbonate - a first-line phosphate binder? Semin Dial 2007; 20 (4): 325-328
26. D Haese PC, Spasovski GB, Sikole A et al. A multicentre study on effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; S73-S78. (Pubitemid 36605868)
27. Hergesell O, Ritz E. Stabilised polymer iron hydrochloride is an effective oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863-867 (Pubitemid 29155137)
28. Hsu CH, Patel SR, Young EW. New phosphate binding agents: Ferric compounds. J Am Soc Nephrol 1999; 10: 1274-1280
29. Sampath Kumar K, Selvam M, Sooraj YS et al. Extended release nicotinic acid - a noval oral agent for phosphate control. Int Uro Nephrol 2006; 38 (1): 171-174 (Pubitemid 43299838)
30. Savica V, Calo L, Santoro D et al. Salivary phosphate excretion in CKD. J Ren Nutr 2008; 18 (1): 87-90.
31. Kutlmann MK, Hoechst S, Landthaler I. Patient impowerment in the management of hyperphospataemia. Int J Artif Organs 2007; 30 (11): 1008-1113.